Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production.[9][10]
Since CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.[11] Since 2011 treatments targeting CD19 have begun to enter trials.[12][13][14] Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the MYC oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than suspected [15][16]
CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.[17]
Product name
Anti CD19 Monoclonal
Tested applications Flow cytometry, ELISA, WB, IHC and functional assays
Immunogen
CD19
Form Liquid
Storage instructions Heat stable , shipped at ambient temp Upon delivery aliquot and store in fridge , longterm storage at -20°C.
"We produced a hybridoma designated 4G7 from a mouse immunized with chronic lymphocytic leukemia cells. The 4G7 hybridoma secretes an IgG1 antibody that is specific for normal and malignant B lymphocytes. Using dual color immunofluorescence staining, this antibody reacted with all immunoglobulin-positive cells but no T cells in normal peripheral blood. There was no detectable 4G7 antigen on monocytes, platelets, red cells, granulocytes, or phytohemagglutinin-activated T cells. When PBL were depleted of 4G7 positive cells and stimulated with pokeweed mitogen, secreted immunoglobulin levels fell to less than 10% of control values on Day 5 and less than 1% of control on Day 7. This antibody was reactive with 155 of 176 B lineage neoplasms on which it was screened. Thirty-five cases of myeloid or T-lymphoid malignancy were negative. Our studies show that the 4G7 antigen modulates in the presence of excess antibody. Free 4G7 antigen was not found circulating in human serum. The cell surface antigen identified by 4G7 was sensitive to pronase proteolysis but resistant to trypsin and chymotrypsin digestion. A comparison of 4G7 with other known B-cell antibodies indicates that the 4G7 antigen has not been previously identified. This antibody is of use for the identification of normal B lymphocytes, the study of B-cell differentiation, and the characterization of lymphoid malignancies."
To order, please use our online cart buttons on each page. You can use Paypal or Major Credit cards.
Alternatively you can email your purchase requisition with P.O. number, catalog numbers, quantity, and shipping & billing addresses to: